Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers.

Current opinion in oncology - 1 Mar 2023

Tas Liselotte, Jedema Inge, Haanen John B A G

Abstract excerpt

PURPOSE OF REVIEW: Treatment with tumor-infiltrating lymphocytes (TILs) has shown remarkable clinical responses in patients with advanced solid tumors. Although the TIL production process is very robust, the original protocol stems from the early nineties and lacks effective selection for tumor-reactivity and functional activity. In this review we highlight the limitations of the current production process and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy and Immune Responses

Share to Lymphocytes, Tumor-Infiltrating

Share to Neoplasms

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 36607824
DOI: 10.1097/CCO.0000000000000925
PMCID: PMC9894146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers.PMID 36607824Read ↗

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapySemantic proximity Read ↗

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Semantic proximity Read ↗

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.Semantic proximity Read ↗

Rational design of a SOCS1-edited tumor infiltrating lymphocyte therapy for solid tumors using CRISPR/Cas9 screensSemantic proximity Read ↗

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.Semantic proximity Read ↗

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapiesSemantic proximity Read ↗

From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer ImmunotherapySemantic proximity Read ↗

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy.Semantic proximity Read ↗

Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screensSemantic proximity Read ↗

Enhancing Patient Lymphocyte Response to Peritoneal Malignancies Using a Personalized Immunocompetent Microfluidic Co-Culture PlatformSemantic proximity Read ↗

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsSemantic proximity Read ↗

Emerging Cellular Therapies for CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.